TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00200174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane followed by combination therapy
Description: Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
Study: NCT03421145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Oral Rinse
Description: The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control Oral Rinse
Description: The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PerioShield™ Oral Health Rinse
Description: PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Purified bottled water containing no active ingredients.
Study: NCT00637000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine soluble film
Description: Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone film strip
Description: Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
Study: NCT03611777

Intervention type: DRUG
Intervention: Inhaled corticosteroid
Description: Drug
Study: NCT03036488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Description: For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
Study: NCT04471480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC/PD-1 inhibitor/anlotinib
Description: chemotherapy and immunotherapy plus antiangiogenic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC/PD-1 inhibitor/anlotinib
Description: chemotherapy and immunotherapy plus antiangiogenic therapy

Intervention type: DRUG
Group type: OTHER
Intervention: TC/PD-1 inhibitor/anlotinib
Description: chemotherapy and immunotherapy plus antiangiogenic therapy
Study: NCT00703599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-derived Stem cells
Description: Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
Study: NCT02177955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 mg diazepam
Description: 10 mg midazolam 45 minutes before surgery
Study: NCT00007878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT06541366

Intervention type: OTHER
Intervention: case-control study
Description: physical examination and Survey Form

Intervention type: OTHER
Intervention: case-control study
Description: physical examination and Survey Form
Study: NCT01758302

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple physical task
Description: Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complex physical task
Description: Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
Study: NCT03036488

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Description: For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
Study: NCT02291523

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbial Transplant
Description: Fecal Transplant via Colonoscopy.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Fecal Microbial Transplant
Description: Fecal Transplant via Colonoscopy.
Study: NCT02074046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine
Study: NCT04216199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care Ultrasound
Description: Point of care Ultrasound
Study: NCT02987374

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 2011-2012 Fluzone IIV3 (IM)
Description: 2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
Study: NCT04431908

Intervention type: DEVICE
Intervention: olfactory device
Description: A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).

Intervention type: DEVICE
Intervention: olfactory device
Description: A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).
Study: NCT00006471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
Study: NCT02748135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-403 20mg/kg
Description: bi-weekly intravenous doses of TB-403 20mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-403 50mg/kg
Description: bi-weekly intravenous doses of TB-403 50mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-403 100mg/kg
Description: bi-weekly intravenous doses of TB-403 100mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-403 175mg/kg
Description: bi-weekly intravenous doses of TB-403 175mg/kg
Study: NCT02749994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Study: NCT02749994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Study: NCT02074046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cancer stem cell vaccine
Study: NCT00586599

Intervention type: OTHER
Group type: OTHER
Intervention: measurement of inflammatory markers
Description: measuring inflammatory markers and comparing to controls.

Intervention type: OTHER
Group type: OTHER
Intervention: measurement of inflammatory markers
Description: measuring inflammatory markers and comparing to controls.
Study: NCT01758302

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cookies
Description: Participants are asked to taste test chocolate chip cookies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetables
Description: Participants are asked to taste test raw celery or radishes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetables
Description: Participants are asked to taste test raw celery or radishes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetables
Description: Participants are asked to taste test raw celery or radishes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No physical task
Description: As a control, for 2 of the arms, participants are not asked to engage in a physical task
Study: NCT00586599

Intervention type: OTHER
Group type: OTHER
Intervention: measurement of inflammatory markers
Description: measuring inflammatory markers and comparing to controls.
Study: NCT04775602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA
Description: 18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
Study: NCT02955472

Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF3 tablet 150mg
Description: A new formulation(3rd.) of Pregabalin CR tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF3 tablet 150mg
Description: A new formulation(3rd.) of Pregabalin CR tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF1 tablet 150mg
Description: A new formulation(1st.) of Pregabalin CR tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF1 tablet 150mg
Description: A new formulation(1st.) of Pregabalin CR tablet
Study: NCT02008591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique
Description: Three different techniques, using the same medications (bupivacaine and fentanyl)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique
Description: Three different techniques, using the same medications (bupivacaine and fentanyl)
Study: NCT02008591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique
Description: Three different techniques, using the same medications (bupivacaine and fentanyl)
Study: NCT02343003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency
Description: Delivery of energy to ablate sensory nerves via cooled radiofrequency probe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Delivery of corticosteroid into knee by injection with needle to reduce knee pain
Study: NCT02243241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYD
Description: Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg \[(1) 40 mg tablet + (1) 120 mg tablet\] (day 15) extended-release tablets administered orally every 24 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
Study: NCT02222350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg DS-8500a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75mg DS-8500a tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00653770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP85A
Description: Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10\^7 pfu)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP85A
Description: Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10\^7 pfu)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP85A
Description: Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10\^7 pfu)
Study: NCT02243241

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo for HYD
Description: Placebo to match HYD tablets administered orally every 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for HYD
Description: Placebo to match HYD tablets administered orally every 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxacin
Description: Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for moxifloxacin
Description: Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
Study: NCT03137654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Affective Training
Description: Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Training
Description: Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
Study: NCT00886067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Solution, oral, single dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2-[18F]-F-A85380
Description: iv, single dose
Study: NCT00653770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10\^7 pfu)
Study: NCT01939886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine - Artesunate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Study: NCT02450630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strenghtened referral of children
Description: Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated \& severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
Study: NCT02475135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
Study: NCT00952796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: moxifloxacin 400mg once daily (IV form, 60minutes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin/sulbactam
Description: ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
Study: NCT05849883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 mg Capsules
Description: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg Capsules
Description: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
Study: NCT00355147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician stroke guideline adherence
Description: Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Self Management
Description: Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Group
Description: Received Phone Calls from Staff to Control for Attention
Study: NCT02288091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine
Description: Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
Study: NCT02587507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Individuals will consume the HFHC meal with 500mL of orange juice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Individuals will consume the HFHC meal with 500mL of water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water with glucose
Description: Individuals will consume the HFHC meal with 500mL of water with glucose.
Study: NCT02223936

Intervention type: OTHER
Group type: OTHER
Intervention: group exposed
Description: Assessment by Brunet Lezine scale

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Not exposed group
Study: NCT00438607

Intervention type: DRUG
Group type: OTHER
Intervention: BIIB014
Description: oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: BIIB014
Description: oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo for MTD or MTD-1
Study: NCT01387711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (Ingenol mebutat Gel, 0.05 %)
Description: All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
Study: NCT01450202

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: bowel insufflation gas
Description: air insufflation, during colonoscopy and esophagogastroduodenoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bowel insufflation gas
Description: CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
Study: NCT00466102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD001
Description: Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets are taken once daily during study therapy
Study: NCT03582605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: see previous descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: see previous descriptions
Study: NCT01426243

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Yellow fever vaccination (STAMARIL)
Description: Yellow fever vaccination (STAMARIL)